	US 12,246,007 B2
	Liquid bendamustine pharmaceutical compositions
Andrew Malcolm Knill, Sydney (AU); and Noel Norris, Sydney (AU)
Assigned to HOSPIRA AUSTRALIA PTY LTD, Sydney (AU)
Appl. No. 17/268,780
Filed by HOSPIRA AUSTRALIA PTY LTD, Sydney (AU)
PCT Filed Aug. 14, 2019, PCT No. PCT/IB2019/056903 § 371(c)(1), (2) Date Feb. 16, 2021, PCT Pub. No. WO2020/035806, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/815,376, filed on Mar. 8, 2019.
Claims priority of provisional application 62/723,725, filed on Aug. 28, 2018.
Claims priority of provisional application 62/764,975, filed on Aug. 17, 2018.
Prior Publication US 2021/0275500 A1, Sep. 9, 2021
Int. Cl. A61K 31/4184 (2006.01); A61K 9/00 (2006.01); A61K 47/10 (2017.01)

CPC A61K 31/4184 (2013.01) [A61K 9/0019 (2013.01); A61K 47/10 (2013.01)]

1 Claim

1. A concentrated liquid pharmaceutical composition comprising a) 25 mg/mL of bendamustine hydrochloride b) 23.7 mg/mL of absolute ethanol, c) 1 mg/mL butylated hydroxyanisole, d) 30 mg/mL water for injection, and 4) polyethylene glycol 400 quantity sufficient, wherein the pharmaceutical composition is, after dilution, suitable for administration to a mammal by injection.